Peptide Profile

Pinealon

EDR Peptide Bioregulator

Research Only10 sourcesShop Pinealon

Overview

Composition

Synthetic tripeptide bioregulator composed of glutamic acid, aspartic acid, and arginine (Glu-Asp-Arg sequence)

Mechanism of Action

Crosses cellular and nuclear membranes, interacts with DNA to modulate gene expression, enhances protein synthesis in neural tissues, suppresses reactive oxygen species (ROS) accumulation, reduces apoptosis, and supports mitochondrial function

Primary Effects

Studied for neuronal stress resilience, cognition-related signaling, and aging-associated brain changes, with support mainly from cell and animal models.

Discovery & Background

Developed in Russia as part of investigations into short peptides derived from brain and pineal gland extracts (e.g., related to Cortexin polypeptide complexes)

Identified as a key active motif (Glu-Asp-Arg) with neuroprotective properties, building on earlier work with pineal-derived compounds; research dates back to the early 2000s and later, focusing on its role in regulating neuronal metabolism, gene activity, and cellular resilience under stress conditions like oxidative damage or hypoxia

Investigational, not approved by major regulatory bodies like the FDA for therapeutic use; interest centered on neuroprotection, cognition, and aging

Research Overview

Most data come from preclinical studies (in vitro cell cultures, rodent models) and limited human observations or small-scale applications

01
Cell and animal studies report antioxidant and neuroprotective effects
02
Suppression of ERK1/2 activation under stress
03
Decreased necrotic/apoptotic cell death
04
Improved cognitive performance in maze tasks
05
Protection against prenatal hyperhomocysteinemia-induced deficits
06
Enhanced neuronal viability in aging or hypoxic models
07
Some studies report signals in Alzheimer's-like models through epigenetic and protein-synthesis pathways
08
Human data are sparse and mostly anecdotal or exploratory in elderly cohorts

No large-scale randomized clinical trials exist; remains investigational

Safety Considerations

Monitoring

Cognitive performance
Mood and emotional stability
Sleep quality
General well-being
Neurological symptoms

Side Effects

Common

Generally well-tolerated in reports
Human adverse-event reporting is limited and not well standardized
Minimal other adverse effects noted in preclinical data

Contraindications

Limited information; caution advised in neurological conditions without oversight
Lacks major regulatory approval for medical use
Evidence predominantly from animal/in vitro studies with very limited human validation

Educational Notice

Pinealon is a short-peptide bioregulator with preclinical literature for neuronal stress, cognition-related signaling, and aging-associated brain models. Evidence is predominantly animal or in vitro, with very limited human validation, and it lacks major regulatory approval for medical use. Clinical decisions require qualified medical oversight.

References